Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 2
2016 2
2018 2
2019 2
2020 1
2021 0
Text availability
Article attribute
Article type
Publication date

Search Results

7 results
Results by year
Filters applied: . Clear all
Page 1
Efficacy of the Antibody-Drug Conjugate W0101 in Preclinical Models of IGF-1 Receptor Overexpressing Solid Tumors.
Akla B, Broussas M, Loukili N, Robert A, Beau-Larvor C, Malissard M, Boute N, Champion T, Haeuw JF, Beck A, Perez M, Dreyfus C, Pavlyuk M, Chetaille E, Corvaia N. Akla B, et al. Among authors: pavlyuk m. Mol Cancer Ther. 2020 Jan;19(1):168-177. doi: 10.1158/1535-7163.MCT-19-0219. Epub 2019 Oct 8. Mol Cancer Ther. 2020. PMID: 31594825 Free article.
Phase I dose-escalation study of F50067, a humanized anti-CXCR4 monoclonal antibody alone and in combination with lenalidomide and low-dose dexamethasone, in relapsed or refractory multiple myeloma.
Fouquet G, Guidez S, Richez V, Stoppa AM, Le Tourneau C, Macro M, Gruchet C, Bobin A, Moya N, Syshenko T, Sabirou F, Levy A, Franques P, Gardeney H, Karlin L, Benboubker L, Ouali M, Vedovato JC, Ferre P, Pavlyuk M, Attal M, Facon T, Leleu X. Fouquet G, et al. Among authors: pavlyuk m. Oncotarget. 2018 May 8;9(35):23890-23899. doi: 10.18632/oncotarget.25156. eCollection 2018 May 8. Oncotarget. 2018. PMID: 29844860 Free PMC article.
Phase I dose-escalation study of F14512, a polyamine-vectorized topoisomerase II inhibitor, in patients with platinum-refractory or resistant ovarian cancer.
Leary A, Le Tourneau C, Varga A, Sablin MP, Gomez-Roca C, Guilbaud N, Petain A, Pavlyuk M, Delord JP. Leary A, et al. Among authors: pavlyuk m. Invest New Drugs. 2019 Aug;37(4):693-701. doi: 10.1007/s10637-018-0688-4. Epub 2018 Dec 14. Invest New Drugs. 2019. PMID: 30547316 Free PMC article. Clinical Trial.
Monotherapy with pixantrone in histologically confirmed relapsed or refractory aggressive B-cell non-Hodgkin lymphoma: post-hoc analyses from a phase III trial.
Pettengell R, Sebban C, Zinzani PL, Derigs HG, Kravchenko S, Singer JW, Theocharous P, Wang L, Pavlyuk M, Makhloufi KM, Coiffier B. Pettengell R, et al. Among authors: pavlyuk m. Br J Haematol. 2016 Sep;174(5):692-9. doi: 10.1111/bjh.14101. Epub 2016 Apr 26. Br J Haematol. 2016. PMID: 27118109 Free PMC article. Clinical Trial.
[Safety and efficacy of bevacizumab combined with taxanes in the first-line treatment of metastatic breast cancer: ATHENA study-France].
Hardy-Bessard AC, Delva R, Pivot X, Espié M, Dalenc F, Coulon Sfairi MA, Monnier A, Serin D, Veyret C, Lortholary A, Pavlyuk M, Kockler L, Pierga JY. Hardy-Bessard AC, et al. Among authors: pavlyuk m. Bull Cancer. 2012 Jun;99(6):609-18. doi: 10.1684/bdc.2012.1586. Bull Cancer. 2012. PMID: 22665515 Free article. Clinical Trial. French.
Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study.
Pierga JY, Petit T, Delozier T, Ferrero JM, Campone M, Gligorov J, Lerebours F, Roché H, Bachelot T, Charafe-Jauffret E, Pavlyuk M, Kraemer S, Bidard FC, Viens P. Pierga JY, et al. Among authors: pavlyuk m. Lancet Oncol. 2012 Apr;13(4):375-84. doi: 10.1016/S1470-2045(12)70049-9. Epub 2012 Feb 28. Lancet Oncol. 2012. PMID: 22377126 Clinical Trial.